These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 33135077)

  • 1. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
    Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
    Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions.
    Zuurbier CJ; Baartscheer A; Schumacher CA; Fiolet JWT; Coronel R
    Cardiovasc Res; 2021 Dec; 117(14):2699-2701. PubMed ID: 33792689
    [No Abstract]   [Full Text] [Related]  

  • 6. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na
    Uthman L; Li X; Baartscheer A; Schumacher CA; Baumgart P; Hermanides J; Preckel B; Hollmann MW; Coronel R; Zuurbier CJ; Weber NC
    Biomed Pharmacother; 2022 Feb; 146():112515. PubMed ID: 34896968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
    Trum M; Riechel J; Schollmeier E; Lebek S; Hegner P; Reuthner K; Heers S; Keller K; Wester M; Klatt S; Hamdani N; Provaznik Z; Schmid C; Maier L; Arzt M; Wagner S
    Cardiovasc Res; 2024 Jul; 120(9):999-1010. PubMed ID: 38728438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1.
    Silva Dos Santos D; Turaça LT; Coutinho KCDS; Barbosa RAQ; Polidoro JZ; Kasai-Brunswick TH; Campos de Carvalho AC; Girardi ACC
    Sci Rep; 2023 May; 13(1):8689. PubMed ID: 37248416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin decreases myocardial cytoplasmic Na
    Baartscheer A; Schumacher CA; Wüst RC; Fiolet JW; Stienen GJ; Coronel R; Zuurbier CJ
    Diabetologia; 2017 Mar; 60(3):568-573. PubMed ID: 27752710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
    Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
    Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
    Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
    Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
    Li X; Römer G; Kerindongo RP; Hermanides J; Albrecht M; Hollmann MW; Zuurbier CJ; Preckel B; Weber NC
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide modulates cardiomyocyte pH control through a biphasic effect on sodium/hydrogen exchanger-1.
    Richards MA; Simon JN; Ma R; Loonat AA; Crabtree MJ; Paterson DJ; Fahlman RP; Casadei B; Fliegel L; Swietach P
    Cardiovasc Res; 2020 Oct; 116(12):1958-1971. PubMed ID: 31742355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
    Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
    Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
    Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
    Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
    Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.
    Yurista SR; Silljé HHW; van Goor H; Hillebrands JL; Heerspink HJL; de Menezes Montenegro L; Oberdorf-Maass SU; de Boer RA; Westenbrink BD
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):311-321. PubMed ID: 32185580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.